Endo Merger Pursuant to the transaction agreement (the "Transaction Agreement") between Endo, Inc. ("Endo") and Salvare Merger Sub LLC, a wholly owned subsidiary of the Issuer ("Merger Sub"), on July 31, 2025, Merger Sub merged with and into Endo (the "Merger"), with Endo surviving the Merger as a wholly owned subsidiary of the Issuer. As a result of the Merger, the Endo common stock held of record by certain managed accounts for which the Investment Manager serves as investment manager was cancelled and converted into the right to receive 4,539,148 Ordinary Shares. Additionally, affiliates of GoldenTree hold $11,000,000 of Endo Finance Holdings, Inc.'s 8.500% Senior Secured Notes due 2031; $147,092,630.42 of Endo Finance Holdings, Inc.'s Senior Secured Term Loan due 2031; $38,722,222.23 of MEH, Inc.'s Revolving Credit Facility due 2030; and $318,677,777.77 of MEH, Inc.'s Secured Term Loan due 2030. General The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the board of directors of the Issuer, and other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Ordinary Shares; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the board of directors. To facilitate their consideration of such matters, the Reporting Persons may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Persons will likely take some or all of the foregoing steps at preliminary stages in their consideration of various possible courses of action before forming any intention to pursue any particular plan or direction. Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.